A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Disease Condition Through Home Monitoring of MS Patients

Status: Recruiting
Location: See all (3) locations...
Study Type: Observational
SUMMARY

To measure the effectiveness of a Remote Patient Monitoring solution based on the use of a smart insole wearable device (and associated smart phone app), for monitoring MS patients' condition on a day-to-day basis. The main focus is the objective measurement of gait, given that 75% of people with MS display clinically significant gait impairments. Initial gait lab gold standard data indicate that the Artificial Intelligence (AI)-based digital biomarker will prove to be highly effective at detecting changes in the MS patient's condition.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: f
View:

• Participants must have a diagnosis of Multiple Sclerosis (MS) based on the McDonald criteria, within an age range of 18 to 60.

• The participant must have an Extended Disability Status Scale (EDSS) score at screening less than or equal to 6.5, inclusive.

• The participant cohort will include at least 3 participants at each site exhibiting one of the following gait phenotypes: ataxic, hemiplegic and spastic. (Some participants may exhibit more than one phenotype).

• The participant cohort will include at least 3 participants at each site with a progressive form of MS.

Locations
United States
Massachusetts
Brigham and Women's Hospital
RECRUITING
Boston
Other Locations
Canada
The Ottawa Hospital
COMPLETED
Ottawa
United Kingdom
The Royal London Hospital
RECRUITING
London
Contact Information
Primary
Bruce Ford
bruce.ford@celestrahealth.com
6132940620
Time Frame
Start Date: 2023-07-01
Estimated Completion Date: 2026-03-01
Participants
Target number of participants: 90
Related Therapeutic Areas
Sponsors
Collaborators: University of Ottawa, The Ottawa Hospital, Barts & The London NHS Trust, Brigham and Women's Hospital
Leads: Celestra Health Systems

This content was sourced from clinicaltrials.gov